^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastric Cancer

    Related cancers:
    16h
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1/2, N=296, Active, not recruiting, Inhibrx Biosciences, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • ordastobart (INBRX-106)
    23h
    Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience. (PubMed, J Cancer Res Clin Oncol)
    Zolbetuximab plus chemotherapy was administered to real-world patients with CLDN18.2-positive AGC with acceptable safety profiles and showed preliminary antitumor efficacy. Nevertheless, some adverse events warrant careful monitoring.
    Retrospective data • Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 positive • HER-2 negative + CLDN18.2 positive
    |
    Vyloy (zolbetuximab-clzb)
    1d
    EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=292, Active, not recruiting, ImCheck Therapeutics | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Oct 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    Keytruda (pembrolizumab) • ICT01
    1d
    Proteasome stress activates YAP/TAZ through the RAP2-MAP4Ks-LATS1/2 pathway and its therapeutic implications in solid tumors. (PubMed, Proc Natl Acad Sci U S A)
    In diffuse-type gastric cancer-an aggressive solid tumor with a poor prognosis and limited treatment options-combined inhibition of the proteasome and YAP/TAZ effectively suppresses tumor growth. Therefore, this study identifies proteasome stress as an upstream signal of the Hippo pathway and provides a mechanistic basis for combination cancer therapy.
    Journal
    |
    LATS1 (Large Tumor Suppressor Kinase 1)
    1d
    TransStar101: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=150, Active, not recruiting, Suzhou Transcenta Therapeutics Co., Ltd. | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • osemitamab (TST001)
    1d
    TRAP1 induced cisplatin resistance in gastric cancer cells by regulating oxidative stress. (PubMed, Front Mol Biosci)
    TRAP1 represented a potential biomarker and a therapeutic target in GC treatment. This study provided a new strategy for improving the efficacy of CDDP-based chemotherapy through individualized treatment approaches.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    cisplatin
    1d
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread (clinicaltrials.gov)
    P1/2, N=768, Recruiting, Boehringer Ingelheim | N=582 --> 768 | Trial completion date: Sep 2029 --> Jan 2029 | Trial primary completion date: Sep 2029 --> Jan 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • leucovorin calcium • Ziihera (zanidatamab-hrii) • Hernexeos (zongertinib)
    1d
    RCT of Mobile Apps & FitBit v. Usual Care (clinicaltrials.gov)
    P=N/A, N=107, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Aug 2025 --> Jun 2026 | Trial primary completion date: Aug 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    2d
    Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma (clinicaltrials.gov)
    P3, N=820, Not yet recruiting, Suzhou Transcenta Therapeutics Co., Ltd. | Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Oct 2025 --> Oct 2029
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • osemitamab (TST001)
    2d
    Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) (clinicaltrials.gov)
    P2, N=39, Recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    AiTan (rivoceranib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. (clinicaltrials.gov)
    P3, N=560, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan
    3d
    EsophaCap for the Detection of Early Esophageal Carcinoma (clinicaltrials.gov)
    P=N/A, N=2500, Recruiting, Johns Hopkins University | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date